Relapse after HSCT 2021 | Treating patients relapsed after auto-SCT
Sergio Giralt
• 11 Oct 2021
Sergio Giralt, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on the management of patients who relapse after autologous stem cell transplant (auto-SCT), in particular discussing the role of second transplantation in multiple myeloma and chimeric antigen receptor T-cell (CAR-T) therapy in lymphoma. Dr Giralt also comments on ways in which CAR-T therapies can be made more widely available, highlighting the role of shared care models. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
Disclosures
Sergio Giralt, MD, PhD, discloses links to Amgen, Janssen, Celgene, Quintiles, Pfizer, CSL Behring, Sanof, Adienne, Kite, JAZZ and Actinuum.
